Cytek Biosciences (CTKB) Operating Expenses (2020 - 2026)
Cytek Biosciences filings provide 6 years of Operating Expenses readings, the most recent being $38.5 million for Q4 2025.
- On a quarterly basis, Operating Expenses rose 25.48% to $38.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $144.8 million, a 10.04% increase, with the full-year FY2025 number at $144.8 million, up 10.04% from a year prior.
- Operating Expenses hit $38.5 million in Q4 2025 for Cytek Biosciences, up from $36.7 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $38.5 million in Q4 2025 to a low of $13.4 million in Q1 2021.
- Median Operating Expenses over the past 5 years was $33.2 million (2023), compared with a mean of $29.3 million.
- Biggest five-year swings in Operating Expenses: surged 106.4% in 2021 and later dropped 8.92% in 2024.
- Cytek Biosciences' Operating Expenses stood at $22.3 million in 2021, then skyrocketed by 31.23% to $29.3 million in 2022, then rose by 13.3% to $33.2 million in 2023, then decreased by 7.59% to $30.7 million in 2024, then grew by 25.48% to $38.5 million in 2025.
- The last three reported values for Operating Expenses were $38.5 million (Q4 2025), $36.7 million (Q3 2025), and $34.5 million (Q2 2025) per Business Quant data.